![Chang En Tsai](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Chang En Tsai
Director/Board Member at VECTORITE BIOMEDICAL INC.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ming Chang Ou | M | - | 7 years | |
So Chu Chang | M | - | 5 years | |
Pai Jung Lai | F | - | 5 years | |
Tsung Hsien Yang | M | - | 4 years | |
Hui Ching Yu | F | - | 4 years | |
Chien Ming Tang | M | - | 2 years | |
Chia Hung Chin | M | - |
UWELL Biopharma, Inc.
![]() UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Chun Yu Pan | M | - |
UWELL Biopharma, Inc.
![]() UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Shih Hsing Tsai | M | - | 19 years | |
Ming Kung Yeh | M | - |
UWELL Biopharma, Inc.
![]() UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Ko Chih Liao | M | - |
UWELL Biopharma, Inc.
![]() UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Wen Ching Hsu | M | - |
UWELL Biopharma, Inc.
![]() UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | - |
Hsiang Yueh Meng | M | - | 2 years | |
Kun Qi Jiang | M | - | 1 years | |
Bi Ru Huang | F | - | 4 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Taiwan | 15 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Chang En Tsai
- Personal Network